Cytomegalovirus-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in donor CMV-seropositive recipient CMV-seronegative kidney transplant recipients.

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

Prevymis (letermovir) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/41321121

Ajit P Limaye; Atul Humar; Barbara Haber; Marcus R Pereira; Marta Crespo; Nassim Kamar; Natalya Broyde; Robert P Carroll; Weiwen Wang

Dec 1, 2025